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Abstract
Background
Knowledge of key drivers for antibiotic prescribing in pediatric lower respiratory tract infec-
tion (LRTI) could support rational antibiotic use. Thus, we aimed to determine the impact of
clinical and laboratory factors on antibiotic prescribing in children and adolescents with
febrile LRTI.
Methods
Pediatric patients from the standard care control group of a randomized controlled trial (Pro-
PAED) investigating procalcitonin guided antibiotic treatment in febrile LRTI were included
in a multivariate logistic regression analysis to evaluate the impact of laboratory and clinical
factors on antibiotic prescribing.
Results
The standard care control group of the ProPAED study comprised 165 LRTI patients
(median age: 2.7 years, range: 0.1–16), out of which 88 (55%) received antibiotic treatment.
Factors significantly associated with antibiotic prescribing in patients with complete clinical
and laboratory documentation (n = 158) were C-reactive protein (OR 5.8 for a 10-fold
increase, 95%CI 2.2–14.9), white blood count beyond age-dependent reference range (OR
3.9, 95%CI 1.4–11.4), body temperature (OR 1.7 for an increase by 1˚C, 95%CI 1.02–2.68),
and pleuritic pain (OR 2.8, 95%CI 1.1–7.6). Dyspnea (OR 0.3, 95%CI 0.1–0.7) and wheez-
ing (OR 0.3, 95%CI 0.13–0.95) were inversely associated with antibiotic prescribing.
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Conclusion
Laboratory markers were strong drivers of antibiotic prescribing in children with febrile lower
respiratory tract infections, in spite of their known poor prediction of antibiotic need. Building
on current guidelines for antibiotic treatment in children with febrile LRTI, a reliable decision
algorithm for safe antibiotic withholding considering the laboratory and clinical factors evalu-
ated in this study has the potential to further reduce antibiotic prescribing.
Introduction
Lower respiratory tract infections (LRTI) bear high mortality and morbidity in children and
adolescents with community acquired pneumonia (CAP) being the leading cause of death
worldwide with 1.3 million fatal pediatric cases each year [1]. Further, LRTI are associated
with non-fatal complications like pleural effusions, empyema (up to 12% of pneumonia cases)
or necrotizing pneumonia (0.8%) which are feared by both hospital and general physicians [2,
3]. However, identifying patients benefitting from antibiotic treatment among those not in
need remains a major diagnostic challenge. Thus, physicians tend to err on the safe side and
overuse antibiotics according to varied approaches as reflected in the different antibiotic pre-
scription rates across countries and institutions [4–8]. A better understanding of the decision
to prescribe or withhold antibiotics is crucial for future restrictive treatment strategies. Factors
leading to antibiotic prescription are known to be complex [5] and are scarcely elucidated in
the pediatric population. Given that adult studies have identified e.g. a strong impact of C-
reactive protein (CRP) (odds ratio 98.1 for exceeding 50 mg/L) on physicians‘decision to pre-
scribe antibiotic medication for LRTI [9] there is a need for clarification of what sways the
decision to prescribe antibiotics for LRTI in children and adolescents. Thus, we aimed at char-
acterizing the laboratory and clinical drivers of antibiotic prescribing for pediatric LRTI with a
subanalysis of the ProPAED trial [10]. This study was among the first randomized controlled
trials in children evaluating the feasibility and effect of Procalcitonin (PCT) guided treatment
for respiratory tract infections [11, 12] after first observational studies suggested that PCT
might be considered in pediatrics. The ProPAED investigators tested established adult PCT
cut-off ranges in a cohort of pediatric emergency departments of tertiary care centers [13–19].
Methods
Study population
This is a hypothesis generating post-hoc analysis from a randomized controlled trial (Pro-
PAED) evaluating PCT as a biomarker to reduce antibiotic treatment of LRTI in children and
adolescents [10]. Briefly, children and adolescents 1 month to 18 years of age presenting with
LRTI to the pediatric emergency departments of two pediatric tertiary care centers in Switzer-
land between 01/2009 and 02/2010 were included. Acute LRTI was defined by the presence of
fever (38˚C measured in the hospital at study enrolment or at home), and at least one of the
following symptoms: tachypnea, dyspnea, wheezing, late inspiratory crackles, bronchial
breathing, and/or pleural rub. CAP was defined as febrile LRTI with a new or increasing alveo-
lar infiltrate on chest radiograph. In the original ProPAED trial patients were randomized to
the PCT guided intervention group or to the standard care control group with treatment based
on international guidelines [4]. For the analysis of factors associated with antibiotic prescrib-
ing only patients from the standard care control group were included. Follow-up was available
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for 98% of all ProPAED patients and no increase of adverse events was associated with antibi-
otic withholding in either of the treatment groups [10].
Variables
The following variables were included for analysis. As clinical parameters presence or absence
of pleuritic pain, pleural rub, wheezing, tachypnea, dyspnea, late inspiratory crackles, reduced
breathing sound, bronchial breathing, body temperature, and heart and respiratory rate were
chosen. For demographic variables and patient history age, pneumococcal and Haemophilus
influenzae type b vaccination status (as classified according to S1 and S2 Tables), and days of
fever preceding presentation at hospital were included. As laboratory and microbiology
parameters CRP, and white blood cell count (WBC), respiratory syncytial virus (RSV) type A/
B or influenza A/B on nasopharyngeal aspirate (NPA) were included. All laboratory and
microbiological tests were performed at study enrolment. Blood culture results were not
included in this analysis since they were not systematically obtained and therefore available
only in 72 (43%) of patients with 4 positive results.
Definitions
WBC was classified as normal or beyond age-dependent reference range according to refer-
ence values provided by the hospital-specific laboratory (S3 and S4 Tables). Heart rate was
classified as normal or elevated according to age-dependent references ranges (S5 Table) [20],
respiratory rate was classified as elevated if exceeding WHO age-dependent reference ranges
for children up to 5 years of age, and if exceeding percentile 90 as reported by Fleming et al.
for children >5 years of age (S6 Table) [21].
Statistical analysis
Analysis of factors associated with antibiotic prescription. The association of clinical,
demographic and laboratory variables with antibiotic prescribing was assessed using explor-
atory graphical evaluation and univariate logistic regression analysis (S1 Fig). For variables
showing a significant association, sensitivity, specificity, accuracy and area under the receiver
operating characteristics (ROC) curve were calculated as performance measures to predict or
classify antibiotic prescribing. For continuous variables these performance measures were cal-
culated for the best threshold (Youden index) which was determined by ROC analysis. Subse-
quently, variables showing a significant association in univariate analysis were included in a
multivariate logistic regression model, followed by stepwise backward deletion of non-signifi-
cant variables. The predictive performance of the final multivariate model was expressed
regarding accuracy, sensitivity and specificity (using a probability threshold of0.5 for classi-
fication of antibiotic prescribing). Continuous variables were partly transformed (e.g. log-
transformation, categorization) and centered to normal values (instead of zero) for regression
analysis to linearize relationships, according to clinical relevance and graphical evaluation of
the appropriateness of assumed relationships (S2–S5 Figs). Missing data was ignored (com-
plete-case analysis), other than vaccination status and NPA test results, where missingness was
interpreted as incomplete vaccination status or negative NPA test result, respectively. The
global goodness of fit of the final multivariate model was assessed by unweighted sum of
squares statistic (Cessie, van Houwelingen, Copas, Hosmer unweighted sum of squares test)
and residual diagnostics (Pearson residuals were plotted and any points > |3 standard devia-
tions| were investigated); overdispersion was assessed and deemed not to be present if the scale
parameter (estimate of the residual mean square) was within the interval [0.85, 1.15]. The
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relative goodness of fit compared to simpler models following single term deletion was
assessed using the likelihood-ratio test.
Sensitivity analyses. The following three sensitivity analyses were performed: (1) The
interaction between pleuritic pain and age (stratified by 2 years of age), was assessed, since
pain is difficult to be assessed children < 2 years. (2) Elastic net regression was used to verify
robustness of selected covariates. (3) Remaining missing variables (<3%) were multiply
imputed by fully conditional specification using the R package mice and re-tested in the logis-
tic regression analysis [22]. All statistical analyses were performed in R (version 3.2.1; R Devel-
opment Core Team, Vienna, Austria, http://www.r-project.org). Example codes of the main
analyses can be found in the supplemental data (S1 Text).
Ethics
Both the ethics committee of the University of Basel and Kanton Aargau approved the trial
protocol. Written informed consent was obtained from all patients or their care takers. The
trial was registered with the International Standard Randomized Controlled Trial Number
Register (ISRCTN 17057980).
Results
Factors associated with antibiotic prescription
Out of 169 patients in the standard care group, a total of 165 patients with complete data sets
for the current analyses were included. Of these, 93 (56%) received antibiotic treatment
(Table 1). The majority of patients treated with an antibiotic (n = 78, i.e. 84%) received it on
the first day of study inclusion.
Eleven of 19 assessed clinical and laboratory variables showed a significant association with
antibiotic prescribing (Table 2). Of these, eight variables were associated with increased antibi-
otic prescription and three with reduced antibiotic prescription. Corresponding odds ratio
estimates from logistic regression analyses are summarized in Table 2 for all tested clinical and
laboratory variables and illustrated in Fig 1 together with the respective multivariate estimates.
See complete sensitivity for univariate regression analysis in S7 Table.
Fig 2 presents sensitivities and specificities for all eleven variables. The highest sensitivity
was calculated for the absence of the symptom wheezing (90%). However, specificity was low
(51%). Best specificity (92%) was calculated for a normal white blood cell count. However,
here sensitivity was low (50%).
For multivariate logistic regression analysis: 158 patients with complete clinical and labora-
tory findings of all variables were included (Table 3). Of those, 87 (55%) received an antibiotic.
Six of the initially eleven significant variables were retained in this final model, after step-wise
backwards-deletion of non-significant associations. Model diagnostics of goodness of fit and
dispersion did not indicate model misspecification, or preference of simpler models. Multi-
and univariate odds ratio estimates are contrasted in Fig 1.
The multivariate model explained the antibiotic prescribing in 126 patients (accuracy: 80%,
95%CI: 73–86%), with a correct prediction of antibiotic prescription of 83% (sensitivity, 95%
CI: 76–86%) and a correct prediction of withholding antibiotic therapy of 76% (specificity;
95%CI: 69–82%). Characteristics of falsely predicted patients are summarized in S8 Table.
Sensitivity analyses
Subgroup analysis indicated that the association of pleuritic pain with antibiotic prescribing
was reduced in younger children (in< 2 years OR = 1.1, p = 0.896, n = 65) compared to the
Key drivers of antibiotic use in pediatric LRTI
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Table 1. Patients‘ characteristics.
Antibiotic treatment No antibiotic treatment
Total number of patients [n (%)] 93 72
received antibiotic at day 1 78 (84) NA
received antibiotic > day 1 15 (16) NA
antibiotic pretreatment 16 (17) 1 (1)
Clinical diagnosis (at inclusion) [n (%)]
Bronchitis/Bronchiolitis 10 (11) 50 (69)
Bronchitis/Bronchiolitis + Pneumonia 24 (26) 17 (24)
Pneumonia 59 (63) 5 (7)
Radiologic diagnosis [n (%)]
Bronchitis/Bronchiolitis 23 (25) 41 (57)
Bronchopneumonia 49 (53) 11 (15)
Lobar pneumonia 17 (18) 1 (1)
Radiography not performed 4 (4) 19 (26)
Age in years [median (range)] 3.9 (0.1–15.3) 1.9 (0.1–15.5)
< 5 years [n (%)] 57 (61.3) 60 (83.3)
< 2 years [n (%)] 26 (28.0) 39 (54.2)
Temperature [˚C (range)] 38.6 (36.3–40.7), NA = 1 38.2 (35.8–39.9)
Preceding days of fever [days (range)] 3 (1–14), NA = 2 2 (1–12)
Heart rate [1/min (range)] 138 (84–192), NA = 3 141 (88–193), NA = 2
Respiratory rate [1/min (range)] 38 (16–80), NA = 2 40 (18–80), NA = 3
C-reactive protein [mg/L (range)] 37 (3–653), NA = 3 9 (3–144), NA = 1
White blood cell count [G/L (range)] 13.4 (3.3–54.8), NA = 3 9.5 (4.4–24.4)
beyond reference range [n (%)] 46 (50) 6 low, 40 elevated 9 (12) 4 low, 5 elevated
normal [n (%)] 44 (40) 63 (88)
Symptoms at inclusion [n (%)]
Wheezing 9 (10) 37 (51)
Dyspnea 47 (51 57 (79)
Reduced breathing sound 37 (40) 10 (14)
Pleuritic pain 36 (39) 15 (21)
Crackles 20 (22) 24 (33)
Bronchial breathing 16 (17) 7 (10)
Late inspiratory crackles 42 (45) 25 (35)
Pleural rub 2 (2) 0
Vaccination status [n (%)]
Pneumococcal vaccination
Incomplete or unknown 68 (73, NA = 10) 36 (50, NA = 6)
Haemophilus influenzae type b vaccination
Incomplete or unknown 24 (26, NA = 9) 18 (25, NA = 3)
Nasopharyngeal aspirate [n (%)]
Negative or not performed 40 (43, NA = 5) 29 (40, NA = 5)
Human metapneumovirus 13 (14) 5 (7)
Respiratory syncytial virus A/B 7/6 (14) 18/6 (33)
Influenza A /B 5/1 (6) 3/1 (6)
H1N1 5 2
P1V1 1 2
Mycoplasma pneumoniae 7 1
Chlamydophilia pneumoniae 1 -
(Continued )
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Table 1. (Continued)
Antibiotic treatment No antibiotic treatment
Adenovirus 1 1
Combinations 6 4
Hospitalization [n (%)] 61 (66) 34 (47)
Education (mother) [n (%)]
School 15 (17) 21 (30)
Apprenticeship 48 (54) 30 (43)
Technical college 14 (16) 8 (11)
University 12 (13) 11 (16)
NA: not applicable
https://doi.org/10.1371/journal.pone.0185197.t001
Table 2. Variables associated with antibiotic prescribing in univariate logistic regression.
Variable (definition of
baseline)
Baseline antibiotic treatment %
(95%CI)
Univariate OR (95%
CI)
Definition of variable effect Univariate p-
value
C-reactive protein (10 mg/L) 40 (31–50) 9.3 (4.3–19.8) for a 10 fold increase 9.2 x 10−9
Wheezing (absence) 71 (62–78) 0.1 (0.0–0.2) presence of symptom 6.1 x 10−8
WBC (normal for age) 41 (32–51) 7.3 (3.3–16.5) > or < age-dependent reference
range
1.5 x 10−6
Age (0 years) 32 (20–46) 1.4 (1.2–1.7) for each additional year of age until 5
years
0.0002
Temperature (37˚C) 34 (22–47) 2.0 (1.4–2.9) for each additional degree (in ˚C) 0.0002
Dyspnea (absence) 75 (63–85) 0.3 (0.1–0.5) presence of symptom 0.0002
Reduced breathing sound
(absence)
47 (39–56) 4.1 (1.9–9.0) presence of symptom 0.0004
Pneumococcal vaccination
(complete for age)
41 (29–54) 2.7 (1.4–5.2) Incomplete or unknown 0.0026
Preceding days of fever (1
day)
44 (32–54) 1.3 (1.1–1.5) for each additional preceding day of
fever
0.0029
Respiratory syncytial virus +
(negative or unknown NPA
test)
62 (53–70) 0.4 (0.2–0.8) positive NPA test 0.011
Pleuritic pain (absence) 50 (41–59) 2.4 (1.2–4.9) presence of symptom 0.015
Crackles (absence) 60 (51–69) 0.5 (0.3–1.1) presence of symptom 0.090
Bronchial breathing
(absence)
54 (46–62) 1.9 (0.7–5.0) presence of symptom 0.17
Late inspiratory crackles
(absence of symptom)
52 (42–62) 1.5 (0.8–2.9) presence of symptom 0.18
Heart rate (normal for age) 51 (38–64) 1.4 (0.7–2.7) High for age 0.34
Respiratory rate (normal for
age)
53 (41–64) 1.3 (0.7–2.5) High for age 0.39
Hib vaccination
(complete for age)
56 (47–65) 1.0 (0.5–2.1) Incomplete or unknown 0.91
Influenzae
(negative or unknown NPA
test)
56 (49–64) 1.0 (0.2–3.7) positive NPA test 0.96
Pleural rub (absence) 56 (48–63) >10.0 (0-infinity) presence of symptom 0.99
Number of patients included in univariate analysis: n = 165, besides for C-reactive protein: n = 161, temperature: n = 164, heart rate: n = 160, respiratory
rate: n = 160, and WBC: n = 16. NPA: nasopharyngeal aspirate, OR: odds ratio, WBC: white blood cell count. p-values were used to order variables in
decreasing order of statistical significance.
https://doi.org/10.1371/journal.pone.0185197.t002
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OR in the full analysis (OR = 2.4, p = 0.015, n = 165), and older children only (OR = 2.7,
p = 0.037 in patients > = 2 years, n = 100); including a formal interaction term for this age-
dependent association reached however not statistical significance of pleuritic pain in neither
group. Elastic net regression suggested lowest misclassification error (optimal regularization
parameter lambda from 100-fold cross-validation) when 9 covariates are included in a multi-
variate model (CRP, wheezing, WBC, temperature, dyspnea, preceding days of fever, RSV+,
pleuritic pain, crackles). A simpler/more regulized model with only 4 covariates (CRP, Wheez-
ing, WBC, dyspnea) could be favored, when accepting a larger error, within one standard
error of the minimum. Using a higher penalty (alpha = 1, i.e. lasso) for covariable selection,
the same 4 covariates would be selected (CRP, wheezing, WBC, dyspnea) to obtain lowest mis-
classification error.
Results of univariate regression analysis did not significantly change when estimating coef-
ficients from multiply imputed datasets (the same 11 variables showed significant associations
with antibiotic prescribing with a p-value< 0.05). The multivariate regression results changed
slightly, with pleuritic pain removed in backward deletion due to a p-value of 0.056 (compared
to p = 0.038 in the initial analysis); all other 5 variables (CRP, wheezing, WBC, dyspnea, tem-
perature) were retained with a p-value < 0.05.
Discussion
This hypothesis generating study investigated associations of laboratory and clinical findings
with antibiotic prescription in children and adolescents with LRTI presenting to the pediatric
Fig 1. Associations of laboratory and clinical factors with antibiotic prescribing. Odds ratio estimates with 95% confidence intervals
(95%CI) from univariate and multivariate logistic regression analysis. Open circles and dashed lines: univariate OR and 95%CI; variables
are presented in decreasing order of strength of association with antibiotic prescription (p-value, details: see Table 2), grey circles indicate a
non-significant association (p-value 0.05), the OR estimate for pleural rub (OR>>10 with 95%CI ranging from 0-infinity, Table 1) is not
illustrated. Black dots and solid lines: multivariate OR with 95%CI of variables remaining after backward deletion of non-significant variables.
Vertical line: OR = 1 indicating no association with antibiotic prescription, ORs > 1 indicate an association with increased antibiotic
prescription, ORs < 1 indicate an association with reduced antibiotic use. CRP: C-reactive protein. WBC: White blood cell count. Vacc.:
Vaccine. RSV: Respiratory syncytial virus. HR: Heart rate. Hib: Haemophilus influenzae type b.
https://doi.org/10.1371/journal.pone.0185197.g001
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emergency department. The main finding of this study was the strong association of elevated
routine laboratory parameters (CRP and WBC) with increased antibiotic prescribing. Four
clinical factors (dyspnea, body temperature, pleuritic pain and wheezing) were also associated
with antibiotic prescribing and explained, together with the laboratory parameters, 80% of the
antibiotic prescription behavior.
Laboratory parameters associated with increased antibiotic prescription
Although the diagnostic utility of the laboratory values is known to be limited, in this study they
have been found to play a major role for antibiotic prescribing. The strongest association with
Fig 2. Sensitivities and specificities for associations with antibiotic prescribing. Illustration of sensitivities and specificities (dots) with
95% confidence intervals (crosses) of each single variable for antibiotic prescription. Left panel: dichotomous variables. Right panel: For
continuous variables the range of sensitivities and specificities for all possible thresholds is illustrated (gray receiver operating characteristic
curves), as well as the sensitivity and specificity associated with the best threshold estimates. Best threshold estimates (95%CI) were: CRP:
26 (12–55) mg/L, age: 2.1 (1.1–4.8) years, temperature: 38.6 (37.3–38.9) ˚C, preceding fever: 2.5 (1.5–5.5) days. CRP: C-reactive protein.
RSV: Respiratory syncytial virus. WBC: White blood cell count.
https://doi.org/10.1371/journal.pone.0185197.g002
Table 3. Variables associated with antibiotic prescription in multivariate logistic regression.
Variable (definition of baselinea) Effectb (multivariate OR) Definition of effect p-value
C-reactive protein (10 mg/L) 5.8 (2.2–14.9) for a 10 fold increase 0.0003
Dyspnea (absence of symptom) 0.3 (0.1–0.7) presence of symptom 0.008
WBC (normal) 3.9 (1.4–11.4) > or < age-dependent reference range 0.011
Temperature (37˚C) 1.7 (1.0–2.7) for each additional degree (in ˚C) 0.040
Pleuritic pain (absence of symptom) 2.8 (1.1–7.6) presence of symptom 0.038
Wheezing (absence) 0.3 (0.1–0.9) presence of symptom 0.039
aBaseline probability estimate: 40% antibiotic prescription (20–64%).
bVariables removed after stepwise backward deletion of non-significant associations (OR and p-values from full multivariate model): age (OR = 0.97,
p = 0.84), reduced breathing sound (OR = 1.08, p = 0.89), incomplete pneumococcal vaccination status (OR = 0.94, p = 0.91), positive RSV test (OR = 0.51,
p = 0.20), days of fever (OR = 1.20, p = 0.08). OR: Odds ratio. WBC: White blood cell count.
https://doi.org/10.1371/journal.pone.0185197.t003
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prescription of antimicrobial agents was found in the multivariate analysis for higher than nor-
mal CRP. CRP has been shown in the past to have low predictive values as a single and com-
bined biomarker for LRTI in need of antimicrobial treatment [23–25]. In addition, sensitivities
and specificities for differentiation between suspected viral and bacterial LRTI have been
revealed to be highly variable on several occasions [23, 24, 26–28]. Pediatric data on the impact
of CRP on antibiotic prescribing for LRTI is not available to the best of our knowledge. A study
in adults, however, showed a CRP exceeding 50 mg/L to be a strong driver (OR of 98.1) for anti-
microbial prescription, consistent with our results [9]. Along the same lines evidence on CRP-
guided reduction of antibiotic use in adult LRTI is emerging with a recent meta-analysis show-
ing a moderate reduction of antibiotic prescription (ORs 0.30–0.73) when CRP thresholds are
included in treatment decision making [29]. The second strongest association with increased
antibiotic prescription was found for an elevated WBC count. This is somewhat surprising as
weak predictive performance for WBC as single and combined laboratory parameter in pediat-
ric LRTI is well known [26–28, 30–33]. This may be explained by older pediatric data showing
WBC count>15 G/L to be predictive of a good response to antimicrobial treatment in pediatric
pneumonia [34]. However, this study of the 1970s did not etiologically evaluate viral or myco-
plasma species. Modern studies assessing a broader etiologic spectrum showed that the naso-
pharyngeal presence of Mycoplasma pneumoniae, influenza virus, or adenovirus is associated
with elevated WBC as well, blurring its diagnostic performance in LRTI [31–33].
In the ProPAED study, physicians were encouraged to order WBC and CRP at study enrol-
ment in all age groups. This might have introduced bias, as laboratory evaluation is not rou-
tinely necessary in young children. However, including only patients > = 2 years of age in a
subanalysis did not change the result: CRP and WBC remained significantly associated with
antibiotic prescribing (CRP: OR = 7.3 vs 9.3 in full analysis; WBC; OR = 6.3 vs 7.3, (all p-
values< 0.01)).
Clinical parameters associated with increased antibiotic prescription
Clinical parameters predictive for antibiotic prescribing were pleuritic pain and body tempera-
ture. Pleuritic pain may be associated with more severe forms of pneumonia particularly with
exudative pleural effusions or empyema, for which hospitalization and intravenous antibiotic
treatment is required. However, previous studies have shown that sensitivity of pleuritic pain
for severe pneumonic infection in young children is limited as children with any LRTI or non-
complicated CAP can present with chest or abdominal pain without evidence of effusions or
empyema [4, 35]. Further, young children may not be able to adequately locate pleuritic pain
and they might rather state non-specific abdominal pain instead. Toddlers may not be able to
communicate mild pleuritic pain as a symptom. Accordingly, in the sensitivity analysis, pleu-
ritic pain lost its association with antibiotic prescribing in children younger than 2 years. In
the present study population, only five of 48 patients with pleuritic pain had unilateral pleural
effusions determined by expert chest radiograph review, none of them required drainage. An
underestimation of the clinical sign pleuritic pain in young children cannot be excluded.
Body temperature has been shown to be a predictor of antibiotic prescribing in a large Ital-
ian study including all kinds of respiratory tract infections in pediatric primary care setting.
Fever >38˚C resulted in a two-fold chance of being treated with antibiotics (OR 2.34; 95%CI
1.97–2.79) [5], which is in line with our findings. Fever is included in CAP definitions and
reassessment algorithms triggering thorough examination, as persistent fever may indicate
development of complications and complications can predict prolonged fever [36, 37]. How-
ever, fever is common in children with LRTI on first presentation (88–96%) and non-specific
to viral or bacterial etiology and thus need for antibiotic prescription [38].
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Tachypnea is included in WHO, Infectious Diseases Society of America (IDSA) and British
Thoracic Society (BTS) guidelines as a clinical sign for severity of LRTI disease [2, 4, 39]. It is
an easily accessible clinical feature suitable for initial and follow-up evaluation of LRTI. The
present analysis failed in univariate regression analysis to show tachypnea as a predictor of
antibiotic prescribing. One explanation is that tachypnea as a sign of LRTI is observed in both,
viral LRTI and bacterial LRTI [40]. Another explanation might be that clinicians rarely con-
sider this parameter and more likely rely on oxygen saturation.
Incomplete pneumococcal vaccination status was associated with increased antibiotic pre-
scription in univariate regression analyses, but not in the multivariate model. However,
incomplete vaccination might drive physicians to suspect pneumococcal infection in those not
vaccinated, and this may influence their prescription behavior. It may be well possible, that
incomplete vaccination status might be associated with antibiotic use in future studies.
Clinical parameters associated with decreased antibiotic prescription
Wheezing and dyspnea were independently associated with lower rates of antibiotic prescrib-
ing: Particularly wheezing is associated mostly with viral infections, which is also reflected by
international guidelines where antibiotic treatment is not recommended for children with
mild fever, wheeze, and signs of upper respiratory tract infections [2, 4].
In multivariate analysis, the combination of six factors including CRP, dyspnea, WBC, body
temperature, pleuritic pain and wheezing explained 80% of antibiotic prescribing and resulted
in more than half of the patients presenting with LRTI to the emergency departments being
treated with antibiotics. Importantly the present study demonstrates that there may be an oppor-
tunity for further reduction of antibiotic prescribing for febrile LRTI based on the availability of
improved biomarkers and clinical parameters. Although some clinical symptoms did not show a
statistically significant association with antibiotic prescription in our study (like bronchial
breathing, late inspiratory crackles, elevated heart/respiratory rate, pleural rub, all with OR point
estimates< 2.0), their consideration in future larger studies could still be of advantage: with our
sample size we calculate a power of only< 60% to detect such a significant univariate OR2.
One limitation of the study is that the impact of chest radiographs on antibiotic prescribing
could not be assessed due to potential selection bias. Chest radiographs were not mandatory
for the initial evaluation during the ProPAED study resulting in chest radiographs being per-
formed in only 87% of all ProPAED patients. However, a background re-assessment of the
chest radiographs based on the WHO standard [41] showed a 66% diagnostic accordance with
the physicians’ emergency room diagnosis (S9 Table). Inter-observer agreement in the evalua-
tion of chest radiographs in previous studies has been shown to be highly variable: depending
on the study setting between 20 to 91% [42–44]. While chest radiographs were not included in
the regression model, this background analysis alone demonstrates the poor accordance of
chest radiographs with clinical diagnosis and consecutive treatment.
A limitation of the original ProPAED trial with a potential impact on this analysis is the
treatment of the intervention group and the standard care control group by the same emer-
gency department team. First, a Hawthorne effect for being under study observation and sec-
ond, a spill-over effect for learning from the rather restrictive PCT guidance intervention
group cannot not be excluded. Especially, as the antibiotic prescription rate was indeed lower
in the ProPAED control group compared to historical controls from the same center [10]. The
fact of being part in a prospective study with the aim to reduce antibiotic prescription might
be an independent factor driving physicians to decreased antibiotic prescription.
A further limitation may be that interactions between patients, parents and physicians were
not included as endpoints in the original ProPAED study. Thus, these variables could not be
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included in the regression analysis. So far, large-scale studies have provided valuable insights
into non-clinical factors influencing physicians when making decisions on LRTI treatment.
Ahmed et al. showed that pediatric patients are at lowest risk for antibiotic exposure when vis-
iting pediatricians in contrast to emergency department doctors or family practitioners, as the
antibiotic prescribing rate in pediatricians is one-third of the rate in emergency department
staff [6]. Moro et al. showed that the physicians’ perception of parents expectations to receive
antibiotic treatment for their child’s LRTI was a strong driver for antibiotic prescribing (OR
12.8), even when this perception was wrong, as revealed in parents interviews before consulta-
tion [5]. These studies have been performed in general practice and influence of parental treat-
ment expectations remain to be elucidated in the tertiary care setting.
Our model did explain 80% of decisions to prescribe antibiotics but leaves 20% unex-
plained. Several large studies as well as the latest meta-analysis of Lucas et al. demonstrated
that a main factor driving antibiotic prescribing in pediatric LRTI is diagnostic uncertainty [5,
45, 46]. However, we have not assessed diagnostic uncertainty in the prescribing physician. As
this may be a significant factor also in tertiary care decision making, we suggest quantification
of this impact in further research.
Conclusions
CRP and WBC were strong drivers of antibiotic prescribing in children with febrile LRTI, in
spite of their known poor predictive value for antibiotic requirement. In contrast, antibiotics
were used prudently in patients with dyspnea and wheezing. Building on current guidelines
for antibiotic treatment in children with febrile LRTI, a reliable decision algorithm for safe
antibiotic withholding considering the laboratory and clinical factors evaluated in this study
may have the potential to further reduce antibiotic prescribing.
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